Detecting progression in GEP-NETs
A Phase III, multicenter, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 2 and Grade 3 advanced GEP-NET
A Phase II, multicenter, open-label study to evaluate safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor—positive gastroenteropancreatic neuroendocrine tumors (GEP-NET) and pheochromocytomas and paragangliomas (PPGL)
A Phase Ib dose-finding study assessing the activity of [177Lu]Lu-DOTA-TATE in newly-diagnosed giloblastoma (GBM) in combination with radiotherapy with or without temozolomide, and in recurrent GBM as a single agent
A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-DOTA-TATE in newly diagnosed ES-SCLC in combination with carboplatin, etoposide, and tislelizumab in induction and with tislelizumab in maintenance treatment phase
SSTR-targeted peptide receptor radionuclide therapy
GRPR-targeted radioligand therapy
This site may contain information of products which have not been authorized in your country.
Please note that the following content is exclusively addressed to healthcare professionals and its correct interpretation requires specialized training.
Are you a healthcare professional?